Treatment Resistant Depression Market Revenue to Expand Significantly by 2032, States DelveInsight Report | Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutic

The Key Treatment Resistant Depression Companies in the market include - Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, Navitor Pharmaceuticals, Denovo Biopharma, Perception Neuroscience, and others.

DelveInsight's "Treatment Resistant Depression Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Treatment Resistant Depression, historical and forecasted epidemiology as well as the Treatment Resistant Depression market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Treatment Resistant Depression, offering comprehensive insights into the Treatment Resistant Depression revenue trends, prevalence, and treatment landscape. The report delves into key Treatment Resistant Depression statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Treatment Resistant Depression therapies. Additionally, we cover the landscape of Treatment Resistant Depression clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Treatment Resistant Depression treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Treatment Resistant Depression space.

To Know in detail about the Treatment Resistant Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Treatment Resistant Depression Market Forecast [https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Treatment Resistant Depression Market Report:

*
The Treatment Resistant Depression market size was valued ~USD 3,100 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In October 2024, Denovo Biopharma LLC, a leader in utilizing precision medicine for the development of innovative drugs, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DB104 (liafensine) for the treatment of patients with treatment-resistant depression (TRD). Fast Track designation can accelerate the review process for drugs intended to treat serious or life-threatening conditions and that show potential to meet an unmet medical need for such conditions.

*
In March 2024, atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, announced today encouraging initial results from Beckley Psytech's Phase 2a open-label study of BPL-003 in Treatment Resistant Depression (TRD), a condition impacting roughly 100 million people globally

*
In 2022, the United States held the largest share of the Treatment-Resistant Depression market among the 7MM, with a market size of approximately USD 2,400 million. This figure is projected to grow further by 2032.

*
In 2022, the UK had a market size of approximately USD 110 million, and it is projected to grow further during the forecast period.

*
In January 2025, The FDA approved Johnson & Johnson's Spravato (esketamine) as the first and only standalone treatment specifically for treatment-resistant depression (TRD).

*
In November 2024, In Q3 2024, atai Life Sciences shared updates on its pipeline, highlighting the FDA's approval of an Investigational New Drug (IND) application for VLS-01, a buccal film formulation of DMT. The company aims to commence a Phase 2 trial of VLS-01 for treatment-resistant depression by the end of the year. Furthermore, atai is on schedule to initiate a Phase 2 study of EMP-01 (oral R-MDMA) for social anxiety disorder by late 2024.

*
In October 2024, Denovo Biopharma LLC announced that the FDA has awarded Fast Track designation to DB104 (liafensine), a treatment under development for treatment-resistant depression (TRD). This designation could accelerate the review process for DB104, a therapy aimed at addressing the significant unmet need for patients unresponsive to standard antidepressant treatments.

*
Key Treatment Resistant Depression Companies: Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, Navitor Pharmaceuticals, Denovo Biopharma, Perception Neuroscience, and others

*
Key Treatment Resistant Depression Therapies: SPRAVATO (esketamine), MIJ821, COMP360 (Psilocybin), GH001, VLS-01-203 BU, BPL-003, Psilocybin, NV-5138, Liafensine, Psilocybin, PCN-101, and others

*
The Treatment Resistant Depression market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Treatment Resistant Depression pipeline products will significantly revolutionize the Treatment Resistant Depression market dynamics

*
Emerging therapies for Treatment-Resistant Depression, such as Novartis' MIJ821, COMPASS Pathways' COMP360 (Psilocybin), Beckley Psytech's BPL-003, Navitor Pharmaceuticals' NV-5138, and others, hold the potential to significantly impact and drive growth in the Treatment-Resistant Depression market.

*
In 2022, the total diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM were around 6,409,000 and are expected to rise throughout the forecast period (2023-2032.

*
In 2022, the United States accounted for the majority of diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM, comprising approximately 71% of the total cases. In comparison, the EU4 and the UK represented around 25%, while Japan contributed approximately 4% of the diagnosed cases in the 7MM.

*
According to DelveInsight, approximately 512,000 cases of Treatment-Resistant Depression were reported in males and 1,117,000 cases in females across the EU4 and the UK in 2022. These numbers are expected to rise over the forecast period.

*
In 2022, the highest number of Treatment-Resistant Depression cases in the US was observed in individuals aged 50-60 years, while the lowest number was recorded in the 18-29-year age group.

Treatment Resistant Depression Overview

Treatment-Resistant Depression (TRD) refers to a form of major depressive disorder (MDD) that does not respond adequately to standard antidepressant treatments. Patients are typically diagnosed with TRD if their symptoms persist despite undergoing at least two different antidepressant therapies, each at an adequate dose and duration.

Get a Free sample for the Treatment Resistant Depression Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market [https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Treatment Resistant Depression Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Treatment Resistant Depression Epidemiology Segmentation:

The Treatment Resistant Depression market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Treatment Resistant Depression

*
Prevalent Cases of Treatment Resistant Depression by severity

*
Gender-specific Prevalence of Treatment Resistant Depression

*
Diagnosed Cases of Episodic and Chronic Treatment Resistant Depression

Download the report to understand which factors are driving Treatment Resistant Depression epidemiology trends @ Treatment Resistant Depression Epidemiology Forecast [https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Treatment Resistant Depression Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Treatment Resistant Depression market or expected to get launched during the study period. The analysis covers Treatment Resistant Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Treatment Resistant Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Treatment Resistant Depression Therapies and Key Companies

*
SPRAVATO (esketamine): Johnson & Johnson

*
MIJ821: Novartis

*
COMP360 (Psilocybin): COMPASS Pathways

*
GH001: GH Research Ireland Limited

*
VLS-01-203 BU: atai Therapeutics, Inc.

*
BPL-003: Beckley Psytech Limited

*
Psilocybin: COMPASS Pathways

*
NV-5138: Navitor Pharmaceuticals

*
Liafensine: Denovo Biopharma

*
Psilocybin: COMPASS Pathway

*
PCN-101: Perception Neuroscience

Discover more about therapies set to grab major Treatment Resistant Depression market share @ Treatment Resistant Depression Treatment Landscape [https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Treatment Resistant Depression Market Drivers

*
Emerging Treatment Resistant Depression Therapies

*
Increased Awareness and Diagnosis

*
Advances in Personalized Medicine

*
Rising Prevalence of Depression

*
Improved Access to Mental Health Care

*
Government and Institutional Support

Treatment Resistant Depression Market Barriers

*
High Cost of Treatments

*
Limited Availability of Effective Therapies

*
Stigma Surrounding Mental Health

*
Side Effects and Safety Concerns

*
Regulatory Challenges

*
Lack of Long-term Data

Scope of the Treatment Resistant Depression Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Treatment Resistant Depression Companies: Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, Navitor Pharmaceuticals, Denovo Biopharma, Perception Neuroscience, and others

*
Key Treatment Resistant Depression Therapies: SPRAVATO (esketamine), MIJ821, COMP360 (Psilocybin), GH001, VLS-01-203 BU, BPL-003, Psilocybin, NV-5138, Liafensine, Psilocybin, PCN-101, and others

*
Treatment Resistant Depression Therapeutic Assessment: Treatment Resistant Depression current marketed and Treatment Resistant Depression emerging therapies

*
Treatment Resistant Depression Market Dynamics: Treatment Resistant Depression market drivers and Treatment Resistant Depression market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Treatment Resistant Depression Unmet Needs, KOL's views, Analyst's views, Treatment Resistant Depression Market Access and Reimbursement

To know more about Treatment Resistant Depression companies working in the treatment market, visit @ Treatment Resistant Depression Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Treatment Resistant Depression Market Report Introduction

2. Executive Summary for Treatment Resistant Depression

3. SWOT analysis of Treatment Resistant Depression

4. Treatment Resistant Depression Patient Share (%) Overview at a Glance

5. Treatment Resistant Depression Market Overview at a Glance

6. Treatment Resistant Depression Disease Background and Overview

7. Treatment Resistant Depression Epidemiology and Patient Population

8. Country-Specific Patient Population of Treatment Resistant Depression

9. Treatment Resistant Depression Current Treatment and Medical Practices

10. Treatment Resistant Depression Unmet Needs

11. Treatment Resistant Depression Emerging Therapies

12. Treatment Resistant Depression Market Outlook

13. Country-Wise Treatment Resistant Depression Market Analysis (2019-2032)

14. Treatment Resistant Depression Market Access and Reimbursement of Therapies

15. Treatment Resistant Depression Market Drivers

16. Treatment Resistant Depression Market Barriers

17. Treatment Resistant Depression Appendix

18. Treatment Resistant Depression Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=treatment-resistant-depression-market-revenue-to-expand-significantly-by-2032-states-delveinsight-report-johnson-johnson-novartis-compass-pathways-gh-research-ireland-limited-atai-therapeutic]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.